All News
Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Read Article
Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
Read Article
RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Biologics Beneficial in Eosinophilic Vasculitis
Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Read Article
Sustained Remission Off Therapy Unlikely in GPA
A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.
Read Article
IL-1 Inhibition Alters Arthroplasty Rates
A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.
Read Article
Fractures from Delays in Denosumab Reinfusions
Denosumab is effective in osteoporosis when used on schedue, but research suggests that discontinuation leads to rapid reversal of effect; a new observational study has shown that delays in denosumab administration of more than 16 weeks results in an increased vertebral fracture risk, according t
Read Article
Systemic Steroids Reduce Mortality in COVID-19
JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.
Read Article
2020 Nobel Prize in Medicine Goes to the Discovery of Hepatitis C
The Nobel Assembly at Karolinska Institutet has awarded the 2020 Nobel Prize in Physiology or Medicine jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. These three scientists made a decisive contribution to the fight against blood-borne hepatitis C, a major global health problem that causes cirrhosis and liver cancer in people around the world.
Read Article
RheumNow Podcast – Function Follows Form (10.2.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.
Defining Difficult Rheumatoid Arthritis
‘Difficult-to-treat RA’ is an oft-used term that carries various clinical qualities and therapeutic disappointments. A EULAR Task Force was established to develop recommendations for the management of difficult-to-treat rheumatoid arthritis and as a first step, have put forth their definition of this rheumatoid arthritis (RA) subset.
Read Article
Low Risk of Latent TB with Secukinumab
TB reactivation and latent tuberculosis infection (LTBI) are warned against with biologic agents, especially TNF inhibitors; yet clinical trial data now shows that the risk of LTBI with IL-17 inhibition via secukinumab is uncommon.
Read Article
Gabapentin Fails to Lessen Chronic Pelvic Pain
Lancet reports that in a randomized, blinded, controlled trial, gabapentin failed to significantly lower pain scores in women with chronic pelvic pain, and was associated with higher adverse event rates compared to placebo.
Read Article
RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.
Read Article
EULAR Updated 2019 Recommendations for Psoriatic Arthritis Management
In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
